KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) FCF Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed FCF Margin for 16 consecutive years, with 47.12% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1174.0% to 47.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 46.15%, a 2.0% increase, with the full-year FY2025 number at 46.15%, up 2.0% from a year prior.
  • FCF Margin was 47.12% for Q4 2025 at Halozyme Therapeutics, down from 50.89% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 104.67% in Q3 2021 to a low of 25.43% in Q2 2024.
  • A 5-year average of 48.68% and a median of 45.38% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 9635bps in 2021, then crashed -7183bps in 2022.
  • Halozyme Therapeutics' FCF Margin stood at 80.74% in 2021, then plummeted by -45bps to 44.14% in 2022, then fell by -14bps to 38.08% in 2023, then soared by 55bps to 58.86% in 2024, then fell by -20bps to 47.12% in 2025.
  • Per Business Quant, the three most recent readings for HALO's FCF Margin are 47.12% (Q4 2025), 50.89% (Q3 2025), and 29.99% (Q2 2025).